Early diagnosis. Grounded
in biology. Powered by AI.

Prof. Lipton is a world-renowned physician-scientist, neurologist, and drug developer best known for first describing the mechanism and contributing to the clinical development of the FDA-approved NMDA receptor antagonist drug, memantine (Namenda®) for Alzheimer’s disease (AD), and for discovering the redox-mediated posttranslational modification of protein S-nitrosylation. As the Step Family Foundation Endowed Chair and Founding Co-director of the Neurodegeneration New Medicines Center at Scripps Research in La Jolla, California, he more recently developed the novel drug, NitroSynapsin, which provides targeted delivery using a memantine-like moiety of an NOx warhead to further offset aberrant NMDA receptor activity. This new drug is currently in development for Autism Spectrum Disorder (ASD) and AD. His prolific research (h-index 158) focuses on developing drugs for neurodegenerative and neurodevelopmental disorders, including AD, PD, and ASD, utilizing advanced human stem cell and cerebral organoid models. Prof. Lipton holds M.D. and Ph.D. degrees from the University of Pennsylvania and also trained at Cornell and at Harvard, where he was on faculty for 25 years prior to moving to La Jolla.

Prof. Kohane is a pioneering leader in the field of Biomedical Informatics, serving as the inaugural Chair of the Department of Biomedical Informatics at Harvard Medical School. He develops and applies computational techniques to address disease at multiple scales: from whole healthcare systems as “living laboratories” to the functional genomics of neurodevelopment with a focus on autism. A visionary whose research agenda is driven by the goal of rapidly converting clinical data into actionable knowledge, he co-authored the influential Institute of Medicine Report on Precision Medicine, setting the national standard for data-driven healthcare transformation. Prof. Kohane leads international efforts to leverage large-scale patient data, 'omic-scale molecular analyses, and AI to accelerate diagnosis and treatment. He holds an MD/PhD from Boston University and continues to practice as a pediatric endocrinologist at Boston Children’s Hospital, ensuring his innovative data strategy is directly applicable to clinical needs.

Eric Klann is Professor and Director of the Center for Neural Science at New York University. Dr. Klann received his Ph.D. from Virginia Commonwealth University School of Medicine in 1989, did postdoctoral training at Baylor College of Medicine, and previously held faculty positions at the University of Pittsburgh and Baylor College of Medicine. Dr. Klann’s research is focused on the molecular mechanisms of translational control and their role in activity-dependent changes in synaptic function and behavior, including cognition. He also studies how dysregulated translational control contributes to altered synaptic function and aberrant behaviors in developmental brain disorders and neurodegenerative disease. Dr. Klann has published over 220 original research articles, reviews, commentaries, and book chapters, and has delivered over 275 invited presentations at universities and conferences all over the world. He has served on numerous journal editorial boards, NIH study sections, international review panels, foundation advisory boards, and councils of scientific organizations. Dr. Klann is the recipient of a NARSAD Distinguished Investigator Award and the Jacob Javits Neuroscience Investigator Award from the National Institutes of Neurological Disorders and Stroke, and is a Fellow of the American Association for the Advancement of Science.